바이오테크 보도자료
-
- Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
- DARMSTADT, Germany--(BUSINESS WIRE)-- Merck, a leading science and technology company, today announced 13 abstracts from the Company’s multiple sclerosis (MS) portfolio will be presented at the 2022 American...
- 2022년 04월 04일
-
- Labcorp Renews Strategic Partnership with Medidata to Provide Suite of Clinical Trial Technologies and Services
- Medidata, a Dassault Systèmes company, announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their...
- 2022년 04월 01일
-
- Waters Introduces Xevo TQ Absolute - The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer
- Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.[i] Waters’ newest high-performance mass spectrometer is...
- 2022년 04월 01일
-
- Yokogawa Successfully Completes Proof of Concept for Optimization of Operations at US Wastewater Reclamation Facility Producing Potable Water
- Yokogawa Electric Corporation (TOKYO: 6841) announces that it has successfully completed a proof of concept test of technology that reduces energy consumption and stabilizes the quality of the water discharg...
- 2022년 03월 31일
-
- Bluehole Publishes an Industry Comment on the World's First E&L Testing Laboratory in the Vaping Industry
- China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry. Here below is the ful...
- 2022년 03월 29일
-
- Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
- Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelumab) subcutaneous injection 300mg syringes for prophylax...
- 2022년 03월 29일
-
- STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder
- STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b t...
- 2022년 03월 28일
-
- Tanner Pharma Increases Europe-Based Inventory of Leukine® to Expand Availability and Enhance Response to Potential Radiation Exposure Due to the Ongoing Conflict in Ukraine
- Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe. ...
- 2022년 03월 25일
-
- ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
- For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the ...
- 2022년 03월 25일
전시회
